The legacy of the blue pill offers a complex case study for investors eyeing pharma. While early sales were astounding, current patent lapse and the arrival of generic versions have considerably impacted revenues. https://blakexgcr311976.jaiblogs.com/68096133/the-blue-pill-and-big-pharma-a-risky-stake